GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Gross Profit

INVO Bioscience (INVO Bioscience) Gross Profit : $1.68 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Gross Profit?

INVO Bioscience's gross profit for the three months ended in Mar. 2024 was $0.73 Mil. INVO Bioscience's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $1.68 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. INVO Bioscience's gross profit for the three months ended in Mar. 2024 was $0.73 Mil. INVO Bioscience's Revenue for the three months ended in Mar. 2024 was $1.58 Mil. Therefore, INVO Bioscience's Gross Margin % for the quarter that ended in Mar. 2024 was 46.07%.

INVO Bioscience had a gross margin of 46.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of INVO Bioscience was 96.51%. The lowest was -3.53%. And the median was 76.08%.


INVO Bioscience Gross Profit Historical Data

The historical data trend for INVO Bioscience's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Gross Profit Chart

INVO Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 0.95 4.02 -0.03 1.09

INVO Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.06 0.39 0.50 0.73

Competitive Comparison of INVO Bioscience's Gross Profit

For the Medical Devices subindustry, INVO Bioscience's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Gross Profit distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Gross Profit falls into.



INVO Bioscience Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

INVO Bioscience's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3.021 - 1.935
=1.09

INVO Bioscience's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1.576 - 0.85
=0.73

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.68 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

INVO Bioscience's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.73 / 1.576
=46.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


INVO Bioscience  (NAS:INVO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

INVO Bioscience had a gross margin of 46.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage


INVO Bioscience Gross Profit Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880